Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jan;34(1):44-53.
doi: 10.1177/0883073818801704. Epub 2018 Oct 22.

A Review of MD STAR net's Research Contributions to Pediatric-Onset Dystrophinopathy in the United States; 2002-2017

Affiliations
Review

A Review of MD STAR net's Research Contributions to Pediatric-Onset Dystrophinopathy in the United States; 2002-2017

Kashika M Sahay et al. J Child Neurol. 2019 Jan.

Abstract

Population studies of rare disorders, such as Duchenne and Becker muscular dystrophies (dystrophinopathies), are challenging due to diagnostic delay and heterogeneity in disorder milestones. To address these challenges, the Centers for Disease Control and Prevention established the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STAR net) in 2002 in the United States. From 2002 to 2012, MD STAR net longitudinally tracked the prevalence, clinical, and health care outcomes of 1054 individuals born from 1982 to 2011 with pediatric-onset dystrophinopathy through medical record abstraction and survey data collection. This article summarizes 31 MD STAR net peer-reviewed publications. MD STAR net provided the first population-based prevalence estimates of childhood-onset dystrophinopathy in the United States. Additional publications provided insights into diagnostic delay, dystrophinopathy-specific growth charts, and health services use. Ongoing population-based surveillance continually improves our understanding of clinical and diagnostic outcomes of rare disorders.

Keywords: dystrophinopathy; muscular dystrophy; population-based; public health surveillance; rare disorders.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting Interests

The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Paul Romitti has received support from PTC Therapeutics Inc. The remaining authors have no conflicts of interest to disclose.

Figures

Figure 1.
Figure 1.
Casea definitions of childhood-onset dystrophinopathy in population-based surveillance systems—definite, probable, possible, asymptomatic, and manifesting female, United States, 2002–2011. a Cases were found through searches for ICD-9 code 359.1 in medical records and ICD-10 code G71.0 in death records.
Figure 2.
Figure 2.
Growth curves comparison for steroid-treated boys with Duchenne muscular dystrophy (DMD) as compared to CDC US Standard growth curves, adapted from Lamb et al (2016).

References

    1. Emery AE. The muscular dystrophies. Lancet. 2002;359(9307): 687–695. - PubMed
    1. Gooch CL, Pracht E, Borenstein AR. The burden of neurological disease in the United States: a summary report and call to action. Ann Neurol. 2017;81(4):479–484. - PubMed
    1. GovTrack. H.R. 717 (107th): MD-CARE Act. https://www.govtrack.us/congress/bills/107/hr717. Published 2001. Accessed October 17, 2017.
    1. Cooperative International Neuromuscular Research Group (CINRG). http://www.cinrgresearch.org/. Published 2018. Accessed June 26, 2018.
    1. Translational Research in Europe for the Assessment and Treatment of Neuromuscular Diseases. http://www.treat-nmd.eu/. Published 2018. Accessed June 26, 2018.

Publication types